BACKGROUND:Spinal cord injury can cause the motor, sensory and autonomic dysfunction below the damaged surface, so the repair of spinal cord injury has been the problem of neuroscience research. OBJECTIVE:To analyze the mechanism, experimental research and clinical application of olfactory ensheathing cel transplantation for the repair of spinal cord injury, and to investigate the effect of olfactory ensheathing cel transplantation on neurological function recovery. METHODS:The basic experimental and clinical researches on olfactory ensheathing cel transplantation for the repair of spinal cord injury were retrospectively analyzed, in order to analyze the relationship between the number and time of the survival cells and the structure and function of the damages spinal cord after olfactory ensheathing cel transplantation. The inclusion and exclusion criteria of the included clinical researches, and the sources, types and transplantation method of the cells used for transplantation were clearly defined, then the effective and objective evaluation criteria was established. RESUTLS AND CONCLUSION:The animal experiments of olfactory ensheathing cel transplantation for the repair of spinal cord injury have achieved satisfactory effects. The spinal cord function score and the sensory and motor function were significantly improved compared with those before transplantation (P<0.001). The successful animal experiment could provide basis for the clinical experiment and application. Parts of the clinical experiments were fol owed-up for 5 years. Because of a smal amount of the cases in the clinical research and the short fol ow-up period, the final recovery of large number of cases cannot judged yet, further observation and research were required. The great significance of the research result is to help to find a reasonable strategy that can make the olfactory ensheathing cells displayed repairing effect sufficiently.

BACKGROUND:A surgery can relieve the increased intracranial pressure, brain tissue edema, and brain stem compression in patients with massive cerebral infarction, and reduce the risk of serious complications, provide more time for medical treatment, and decrease the mortality and disability rate.
OBJECTIVE:To investigate the clinical value of decompressive craniectomy plus temporal muscle sticking therapy of cerebral infarction.
METHODS:A retrospective analysis was performed among the clinical data of 37 cerebral infarction patients, including 24 males and 13 females, they aged 10-55 years old. After decompressive craniectomy plus temporal muscle sticking therapy, the involved patients were fol owed up. The prognosis was evaluated according to the Glasgow Outcome Scale, as excel ent, good, moderate, none, and poor.
RESULTS AND CONCLUSION:At 6 months of fol ow-up, the total efficiency of surgical treatment in 37 patients was up to 89%, including excel ent in 5 cases (14%), good in 15 cases (41%), moderate in 13 cases (35%), none in 4 cases (11%). No cases exhibited aggravation. Thirty-one patients with cerebral infarction were detected by cranial CT scans, among them 19 patients exhibited significantly reduced infarct size, and 12 patients who had self-care ability were found to restore the cerebral cortex activity. During the 1-year fol ow-up, 31 patients completed the fol ow-up, the remaining 6 cases were lost due to contact failure. Twenty-three cases achieved satisfactory long-term results, and returned to normal work and simple labor, two cases occurred contralateral cerebral infarction and became sicker. Decompressive craniectomy plus temporal muscle sticking therapy is an effective treatment for the majority of cerebral infarction.

0) and the correlation coefficient were low.The absence of intravesical occurrence of the cancer in solitary primary tumor cases was significantly less than that in the multiple ones ( P =0).The intravesical occurrence rate of the cancer elevated with the pathological stage of the primary cancer ( P =0.0039).92.5% of cases with initial concurrent involvement of the bladder have had the occurrence of bladder cancer within 2 years after surgical treatment. Conclusions The number and the stage of the primary tumor,with concurrent bladder involvement or not and the internal between the occurrence of the bladder cancer and the upper urinary tract cancer are the significant factors for prognosis,the coefficient correlation between the 4 factors being low.

Objective To verify the presence of tumor necrosis factor receptor (TNF R 2) in spermatozoa of fertile men,and to provide experimental evidence for the direct action of TNF on spermatoza. Methods Using Western blotting the expressions of TNF R 2 in spermatozoa of 15 fertile men were assessed. Results TNF R 2 was expressed in spermatozoa of all the 15 fertile men. Conclusions The spermatozoa of fertile men have TNF R 2,which may transmit the cytokines signal into cytoplasm and modulate the spermatozoa function.

Objective To evaluate the inhibitory effect of endostatin on bladder tumor and to investigate the possible mechanism of the inhibition. Methods (1)By means of MTT method,the effects of endostatin on ECV304 and EJ cells proliferation were studied.(2)Ten nude mice were subcutaneously implanted with EJ bladder tumor cells (1?10 7/ml). After the tumor volume exceeded 100～200 mm 3,the mice were randomized into two groups.One group received recombinant human endostatin (2 mg?kg -1 ?d -1 ) whereas the other group received PBS as control.All the treatment lasted 21 days.(3) After that,the mice were sacrificed and then MMPs and TIMPs mRNA expression were measured in implanted tumor by RT PCR and Western blot method. Results (1)Endostatin inhibits ECV304 proliferation stimulated with bFGF (5 ng/ml).In addition,we report for the first time that endostatin also inhibits EJ cells proliferation.(2)The mean tumor weight of endostatin treated group (0.70?0.16 g) was significantly lower than that of control group (1.14?0.21)g, P

Objective To investigate the inhibitive effect of antisenes oligodeoxynucleotide(ASON) on the phosphodiesterase type 5(PDE5) in smooth muscle cells of human corpus cavernosum,and provide experimental groundwork for the gene therapy of erectile dysfunction. Methods PDE5 gene ASON (containing exon 1) was transfected into the corpus cavernosum smooth muscle cells with the presence of liposome DOTAP.Another sense oligodeoxynucleotide(SON) and 1% of bovine serum were also transducted into the cells as controls.PDE5 was probed and measured by Western blot at 1,2,4,6,10,24 and 48 h after transfection. Results After transfection(1～6 h), PDE5 in human corpus cavernosum smooth muscle cells was significantly lower than it was in controls( P = 0.000 ～0.014). Conclusions The results indicate that PDE5 gene antisense oligodeoxynucleotide has inhibitive effect on PDE5 in smooth muscle cells of human corpus cavernosum in vitro,and the present study provides experimental groundwork for the gene therapy of erectile dysfunction.

Objective To provide an ideal material for the investigation of penile erection. Methods Human corpus cavernosum smooth muscle cells were cultured with DMEM ( 20% of it was human serum)in vitro and the bred cells were identified by immunohistochemistry. Results After 10～14 days, spindle cells overspreaded in 6 culture bottles and they were validated as human corpus cavernosum smooth muscle cells immunohistochemically. Conclusions Human corpus cavernosum smooth muscle cells can be cultivated in feasible medium and can also become a cell line.These bred cells can serve as a material for the study of penile erection.

Objective To evaluate the quantitative determination of urine nuclear matrix protein 22 (NMP-22) and bladder tumor antigen (BTA) in the screening of bladder tumor recurrence. Methods 90 patients who had undergone TURBT were recruited in this study.Standard ELISA test was used to determine the quantity of NMP-22 in urine and urine BTA stat test was also performed.the findings were analyed with reference to the cystoscopic and pathological results. Results In comparison with the results of cystoscopy,urine NMP-22 test might denote 77% (32/43) recurrence of bladder cancer and this positive rate would increase to 93% (40/43) with the combined use of urine NMP-22 and BTA test. Conclusions Examination of NMP-22 in urine is a rapid and effective means of detecting the recurrence of bladder cancer.With the combined use of BTA test,urine NMP-22 determination might be a useful non-invasive method in screening the recurrence of bladder cancer,and the conventional invasive cystoscopy might be avoided.

Objective To explore the relationship between cholecystoadenomyomatosis and gallbladder cancer.Method The expression of p53,bcl-2,EGFR oncoproteins were examined by method of immunohistochemistry in benign lesions and carcinomas in gallbladder.Results The study revealed that overexpressions of p53,bcl-2,EGFR oncoproteins were detected in 0,4,3 cases of 21 patients with chronic cholecystitis;0,5,3 cases of 20 patients with cholecysto-adenomyomatosis and 16,14,11 cases of 25 patients with adenocarcinoma of the gallbladder respectively.There were significantly differences in single or multiple oncogene expression rates among groups,but not in chronic cholecystitis to adenomyomatosis.Conclusions These results suggests that oncogenic changes of p53,bcl-2,EGFR expression may play a role in gallbladder oncogenesis,cholecystoadenomyomaltosis should not be considered as an important precancerous lesion of gallbladder.

Objective To study endostatin expression in tumor tissues and serum levels of bladder cancer patients. Methods Expression of endostatin in 45 cases of bladder cancer and 12 subjects with normal bladder tissues was examined immunohistochemically.Serum levels of endostatin in 58 patients with bladder cancers and 43 healthy controls were analyzed by competitive enzyme immunoassay. Results Positive expression of endostatin was found in 61.5% patients with superficial bladder cancer,90.6% with invasive bladder cancer and 33.3% in normal bladder tissues.Serum level of endostatin was significantly higher in patients with bladder cancer than that in healthy controls (P